Bafna Pharmaceuticals Limited
: BAFNAPH · Pharmaceuticals
Snapshot
Unlock Bafna Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in the manufacturing of finished pharmaceutical formulations. The company produces a diverse range of solid and liquid oral dosage forms, including Betalactam, Non-Betalactam, and Cephalosporin products.
Business Model
The company generates revenue through the manufacturing and sale of over 336 licensed pharmaceutical formulations. It leverages a global registration strategy, having secured regulatory approvals for 78 of its products across various international markets.
- Licensed Formulations:336+
- Globally Registered Products:78
Growth Outlook
Growth is driven by the expansion of the company's product portfolio and the continued registration of its formulations in global markets. The focus remains on maintaining high-quality manufacturing standards for its solid and liquid oral dosage lines.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent international regulatory standards and potential audits of its manufacturing facilities.
- Market Competition. The pharmaceutical sector is highly competitive, which may exert pressure on pricing and profit margins for generic formulations.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) could impact production costs and operational efficiency.
- Currency Risk. As the company pursues global registrations, it remains exposed to foreign exchange rate fluctuations affecting export revenues.
Start your research today
Unlock AI insights, financials, peers and live data on Bafna Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹151 Cr
TTM · standalone
NET PROFIT
₹11 Cr
TTM · standalone
EPS
₹4.69
TTM · standalone
RETURN ON EQUITY
12.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.1%
TTM · standalone
P/E
47.2x
Q4 FY26 · standalone
EV/EBITDA
14.7x
Q4 FY26 · standalone
EBITDA MARGIN
13.7%
TTM · standalone
NET PROFIT MARGIN
6.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Bafna Pharmaceuticals LimitedBAFNAPH | ₹689 Cr | 88.48 | 40.61 | -3.1% | 12.5% | 8.6% | 10.3% | +180.3% |
Amanta HealthcarAMANTA | ₹719 Cr | 44.50 | 13.94 | — | 21.5% | 6.7% | 9.9% | — |
Influx Health.INFLUX | ₹701 Cr | — | — | — | 20.0% | — | — | +77.5% |
Shree Ganesh Remedies LimitedSGRL | ₹696 Cr | 39.23 | 18.75 | — | 34.8% | 11.9% | 15.9% | -7.6% |
Zim LaboratoriesZIMLAB | ₹672 Cr | 153.00 | 19.69 | 7.6% | 9.9% | 1.3% | 5.7% | +66.4% |
Kilitch Drugs (India) LimitedKILITCH | ₹601 Cr | 13.70 | 14.07 | 14.0% | 20.2% | 12.1% | 15.6% | -49.4% |
As of Q1 FY27
Financials
Bafna Pharmaceuticals Limited
: BAFNAPH · Pharmaceuticals
Snapshot
Unlock Bafna Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in the manufacturing of finished pharmaceutical formulations. The company produces a diverse range of solid and liquid oral dosage forms, including Betalactam, Non-Betalactam, and Cephalosporin products.
Business Model
The company generates revenue through the manufacturing and sale of over 336 licensed pharmaceutical formulations. It leverages a global registration strategy, having secured regulatory approvals for 78 of its products across various international markets.
- Licensed Formulations:336+
- Globally Registered Products:78
Growth Outlook
Growth is driven by the expansion of the company's product portfolio and the continued registration of its formulations in global markets. The focus remains on maintaining high-quality manufacturing standards for its solid and liquid oral dosage lines.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent international regulatory standards and potential audits of its manufacturing facilities.
- Market Competition. The pharmaceutical sector is highly competitive, which may exert pressure on pricing and profit margins for generic formulations.
- Supply Chain Volatility. Fluctuations in the cost and availability of active pharmaceutical ingredients (APIs) could impact production costs and operational efficiency.
- Currency Risk. As the company pursues global registrations, it remains exposed to foreign exchange rate fluctuations affecting export revenues.
Start your research today
Unlock AI insights, financials, peers and live data on Bafna Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹151 Cr
TTM · standalone
NET PROFIT
₹11 Cr
TTM · standalone
EPS
₹4.69
TTM · standalone
RETURN ON EQUITY
12.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.1%
TTM · standalone
P/E
47.2x
Q4 FY26 · standalone
EV/EBITDA
14.7x
Q4 FY26 · standalone
EBITDA MARGIN
13.7%
TTM · standalone
NET PROFIT MARGIN
6.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY27